نتائج البحث - Siddhartha Mitra

  • يعرض 1 - 15 نتائج من 15
تنقيح النتائج
  1. 1
    The Ubiquitin-Proteasome Pathway in Huntington's Disease

    The Ubiquitin-Proteasome Pathway in Huntington's Disease حسب Siddhartha Mitra, Steven Finkbeiner

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Single Neuron Ubiquitin-Proteasome Dynamics Accompanying Inclusion Body Formation in Huntington Disease

    Single Neuron Ubiquitin-Proteasome Dynamics Accompanying Inclusion Body Formation in Huntington Disease حسب Siddhartha Mitra, Andrey S. Tsvetkov, Steven Finkbeiner

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Protein turnover and inclusion body formation

    Protein turnover and inclusion body formation حسب Siddhartha Mitra, Andrey S. Tsvetkov, Steven Finkbeiner

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Heterogeneous reallocation of presynaptic efficacy in recurrent excitatory circuits adapting to inactivity

    Heterogeneous reallocation of presynaptic efficacy in recurrent excitatory circuits adapting to inactivity حسب Ananya Mitra, Siddhartha Mitra, Richard W. Tsien

    منشور في 2011
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death

    Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death حسب Montserrat Arrasate, Siddhartha Mitra, Erik S. Schweitzer, Mark R. Segal, Steven Finkbeiner

    منشور في 2004
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Quantitative Relationships between Huntingtin Levels, Polyglutamine Length, Inclusion Body Formation, and Neuronal Death Provide Novel Insight into Huntington's Disease Molecular Pathogenesis

    Quantitative Relationships between Huntingtin Levels, Polyglutamine Length, Inclusion Body Formation, and Neuronal Death Provide Novel Insight into Huntington's Disease Molecular P... حسب Jason Miller, Montserrat Arrasate, Benjamin A. Shaby, Siddhartha Mitra, Eliezer Masliah, Steven Finkbeiner

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma

    Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma حسب Ajay K. Gopal, Michelle A. Fanale, Craig H. Moskowitz, Andrei R. Shustov, Siddhartha Mitra, Weifan Ye, Anas Younes, Alison J. Moskowitz

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Identification of a Brainstem Circuit Controlling Feeding

    Identification of a Brainstem Circuit Controlling Feeding حسب Alexander R. Nectow, Marc Schneeberger, Hongxing Zhang, Bianca C. Field, Nicolas Renier, Estefania P. Azevedo, Bindiben Patel, Yupu Liang, Siddhartha Mitra, Marc Tessier‐Lavigne, Ming‐Hu Han, Jeffrey M. Friedman

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059

    Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059 حسب Harriet S. Walter, Sandrine Jayne, Simon Rule, Guillaume Cartron, Franck Morschhauser, Salvador Macip, Lionel Karlin, Ceri Jones, Charles Herbaux, Philippe Quittet, Nimish Shah, Claire V. Hutchinson, Chris Fegan, Yingsi Yang, Siddhartha Mitra, Gilles Salles, Martin J.S. Dyer

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Carta
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia

    Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia حسب Alexey V. Danilov, Charles Herbaux, Harriet S. Walter, Peter Hillmen, Simon Rule, Ebenezer A. Kio, Lionel Karlin, Martin J.S. Dyer, Siddhartha Mitra, Ping Yi, Rita Humeniuk, Xi Huang, Ziqian Zhou, Pankaj Bhargava, Juliane M. Jürgensmeier, Chris Fegan

    منشور في 2020
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    An in vitro pharmacogenomic approach reveals subtype-specific therapeutic vulnerabilities in atypical teratoid/rhabdoid tumors (AT/RT)

    An in vitro pharmacogenomic approach reveals subtype-specific therapeutic vulnerabilities in atypical teratoid/rhabdoid tumors (AT/RT) حسب David Pauck, Daniel Picard, Mara Maue, Kübra Taban, Viktoria Marquardt, Lena Blümel, Jasmin Bartl, Nan Qin, Nadezhda Kubon, Dominik Schöndorf, Frauke-Dorothee Meyer, Johanna Theruvath, Siddhartha Mitra, Martin Hasselblatt, Michael C. Frühwald, Guido Reifenberger, Marc Remke

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Disease-Associated Polyglutamine Stretches in Monomeric Huntingtin Adopt a Compact Structure

    Disease-Associated Polyglutamine Stretches in Monomeric Huntingtin Adopt a Compact Structure حسب Clare Peters‐Libeu, Jason Miller, Earl Rutenber, Yvonne M. Newhouse, Preethi Krishnan, Kenneth Cheung, Danny M. Hatters, Elizabeth D. Brooks, Kartika Widjaja, Tina Tran, Siddhartha Mitra, Montserrat Arrasate, Luis A. Mosquera, Dean P. Taylor, Karl H. Weisgraber, Steven Finkbeiner

    منشور في 2012
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia

    A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia حسب Susan O’Brien, Nicole Lamanna, Thomas J. Kipps, Ian W. Flinn, Andrew D. Zelenetz, Jan A. Burger, Michael J. Keating, Siddhartha Mitra, Leanne Holes, Albert S. Yu, David M. Johnson, Langdon L. Miller, Yeonhee Kim, Roger Dansey, Ronald L. Dubowy, Steven Coutré

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia

    Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia حسب Jeff P. Sharman, Steven Coutré, Richard R. Furman, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D. Zelenetz, Thomas J. Kipps, Ian W. Flinn, Paolo Ghia, Herbert Eradat, Thomas J. Ervin, Nicole Lamanna, Bertrand Coiffier, Andrew R. Pettitt, Shuo Ma, Eugen Tausch, Paula Cramer, Julie Huang, Siddhartha Mitra, Michael Hallek, Susan O’Brien, Stephan Stilgenbauer

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Identifying polyglutamine protein species in situ that best predict neurodegeneration

    Identifying polyglutamine protein species in situ that best predict neurodegeneration حسب Jason Miller, Montserrat Arrasate, Elizabeth D. Brooks, Clare Peters Libeu, Justin Legleiter, Danny M. Hatters, Jessica Curtis, Kenneth Cheung, Preethi Krishnan, Siddhartha Mitra, Kartika Widjaja, Benjamin A. Shaby, Gregor P. Lotz, Yvonne M. Newhouse, Emily J Mitchell, Alex Osmand, Michelle Gray, Vanitha Thulasiramin, Frédéric Saudou, Mark R. Segal, X. William Yang, Eliezer Masliah, Leslie M. Thompson, Paul J. Muchowski, Karl H. Weisgraber, Steven Finkbeiner

    منشور في 2011
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: